Covariates | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Number of prior therapies | ≥4 | 1.37 (0.73–2.56) | 0.324 |  |  |
Sex | male | 0.65 (0.31–1.37) | 0.261 |  |  |
Age | > 66 | 0.97 (0.53–1.76) | 0.931 |  |  |
ECOG PS | 2 | 1.57 (0.72–3.41) | 0.251 |  |  |
Location of primary tumor | Stomach | 0.59 (0.35–1.37) | 0.222 |  |  |
Histology | diffuse | 0.85 (0.44–1.63) | 0.636 |  |  |
HER2 overexpression | (+) | 1.52 (0.80–2.87) | 0.192 |  |  |
Concomitant use of NSAIDs / antiplatelets / anticoagulation therapy | (+) | 1.12 (0.60–2.11) | 0.709 |  |  |
History of hypertension | (+) | 0.53 (0.27–1.04) | 0.066 |  |  |
Number of metastatic sites | ≥2 | 1.51 (0.83–2.75) | 0.17 |  |  |
Ascites | (+) | 1.78 (0.97–3.26) | 0.061 |  |  |
Peritoneal metastasis | (+) | 1.32 (0.74–2.37) | 0.339 |  |  |
Previous gastrectomy | (+) | 0.48 (0.26–0.89) | 0.019 | 0.50 (0.27–0.94) | 0.031 |
Time from initiation of 1st line therapy | ≥2 years | 0.53 (0.29–0.98) | 0.043 | 0.66 (0.35–1.25) | 0.208 |
Prior history of ICI | (+) | 1.03 (0.52–2.06) | 0.92 |  |  |
ALP | ≥WNL | 1.08 (0.59–1.98) | 0.797 |  |  |
CRP | ≥WNL | 1.34 (0.71–2.51) | 0.359 |  |  |
LDH | ≥WNL | 1.42 (0.74–2.74) | 0.285 |  |  |
NLR | < 2.5 | 0.35 (0.16–0.74) | 0.002 | 0.38 (0.17–0.87) | 0.017 |
PLR | < 250 | 0.58 (0.32–0.97) | 0.033 | 0.83 (0.44–1.56) | 0.413 |